Therapeutic challenges in hepatitis C-infected injection drug using patients

1477-7517-3-31 1477-7517 Review Therapeutic challenges in hepatitis C-infected injection drug using patients Cooper L Curtis ccooper@ottawahospital.on.ca Mills J Edward EMILLS@ccnm.edu

Associate Professor of Medicine-University of Ottawa Hospital, Division of Infectious Diseases-The Ottawa Hospital, Ottawa, Canada

Centre for International Health and Human Rights Studies, Toronto, Canada

Faculty of Health Sciences, Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Canada

Harm Reduction Journal 1477-7517 2006 3 1 31 http://www.harmreductionjournal.com/content/3/1/31 17096852 10.1186/1477-7517-3-31 05 8 2006 10 11 2006 10 11 2006 2006 Cooper and Mills; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Hepatitis C Viral (HCV) infection in the injection drug user (IDU) population is a major medical concern. Concurrent substance abuse, co-morbid mental health conditions, poor socioeconomic status and a complex treatment protocol that is often incompatible with the life styles of IDUs combine to account for poor uptake and completion of HCV treatment. This article discusses HCV antiviral treatment issues relevant to IDUs chronically infected with this virus. The effect of non-injected substances of abuse on treatment outcome is considered. Priority issues requiring research are discussed.

Background

Given its high incidence and prevalence, the complications of chronic hepatitis C virus (HCV) infection will impact the morbidity and mortality of at-risk populations in the developed world for the foreseeable future 1. Those with substance abuse concerns, and particularly injection drug users (IDUs), are at a greater risk of HCV infection 2. In North America, injection drug use remains the primary risk factor for new and chronic infections. In Canada, injection drug use is estimated to account for over half of all current HCV infections 3. Approximately 55% of active and 49% of post injection drug users are HCV infected 3. Although therapy is available for HCV infection, there are multiple obstacles that diminish the likelihood of past and present IDUs receiving combination interferon and ribavirin HCV treatment. In this article, we discuss relevant HCV antiviral treatment issues pertaining to IDUs chronically infected with HCV. We additionally consider the effect of other substances of abuse on treatment and priority issues requiring research.

Influence of substance use on natural history of HCV

Not all individuals with chronic HCV infection will progress to advanced stages of fibrosis and end-stage liver disease. During the initial period of evaluation of a HCV infected patient, the physician formulates an impression regarding the likelihood of poor outcome based on risk factors for rapid progression (e.g. immune suppression, alcohol use), physical examination, laboratory evaluation and liver biopsy. Although the final decision to initiate HCV antiviral therapy is made on a case-by-case basis, treatment is strongly recommended for those having or at least predicted to have more progressive disease.

The practice of drug injection is not known to directly influence the rate of HCV progression despite the potential for multiple repeat exposures to various genotypes and quasi-species. However, there are several factors associated with injection drug use which may contribute to accelerated progression 4. Chief among these is excess alcohol use which is generally defined as more that 50 grams of alcohol per day (i.e. approximately 3–4 beers per day). Concurrent excess alcohol consumption is found in 40% of active IDUs 5. In our own clinic, we found that 75% of past injection drug users have a history of excess alcohol use compared to 32% in those who acquired HCV infection through other means (χ², p < 0.001). In addition to increasing risk behaviors 6, alcohol is well known to accelerate the rate of hepatic fibrosis and reduce the time to cirrhosis in HCV 789. Clearly, concurrent alcohol use in HCV is a factor predicting increased need for HCV therapy but is also a factor limiting eligibility for access to therapy. Furthermore, HCV antiviral therapy efficacy is diminished in those engaging in excess alcohol use (see below). As a primary measure, support for alcohol reduction and cessation is needed in those with HCV, irrespective of injection drug use.

Although not supported by strong evidence, it is plausible that poor nutrition may play a role in influencing HCV progression. Relative malnutrition and micronutrient deficiency likely compromise the livers ability to control chronic infection, contain inflammation and resorb fibrotic material as it is produced 10. Nutrition is often substandard in substance users. Deficient food intake, anorexia, nausea, vomiting, poor gastrointestinal absorption, altered metabolism and increased energetic expenditure contribute to a poor nutritional status in alcoholics 1112 and injection drug users 13.

Factors influencing treatment consideration

Psychiatric health

Psychiatric health is an important variable to consider when determining the initiation of HCV antiviral therapy. Those living with chronic HCV infection and those with current or past injection drug use 14 have a heavy burden of psychiatric illness 15161718. In our clinic, depression was identified in 62% of patients at initial evaluation using the Center for Epidemiologic Studies of Depression Scale (CES-D) 1819. To compound this problem, interferon-based HCV therapies are well-known to increase the frequency and severity of depression 20 and other psychiatric illness 16. The high frequency of depression among HCV-infected patients is multifactoral. As in other populations with chronic illnesses, such as cancer and diabetes, alcohol intake, smoking, and depression often co-occur and influence mental well-being 21222324. The inter-relationships between the bio-psycho-social variables within HCV-infected injection drug users are not fully understood and deserve continued study. We and other groups are evaluating the use of prophylactic antidepressants in those initiating interferon-based HCV treatment 2526.

Socioeconomic challenges

There are several concrete obstacles to the successful delivery of HCV antiviral therapy to IDUs. Suitable shelter is not always available and a lack of safe storage facilities for HCV therapies negates successful adherence and treatment success. The absence of refrigeration, which is required for interferon storage between weekly dosing, may compromise patients' ability to receive HCV therapy. Poor attendance for outpatient clinical assessments is partially explained by limited or cost-prohibitive transportation options.

Other obstacles to treatment are less tangible. Mistrust of the medical community may influence patient willingness to be assessed and initiation of HCV antiviral therapy. This is, in part, fostered by multiple sources of inaccurate or misinterpreted information pertaining to HCV disease and treatment that can be found in the lay literature and on the internet. Another contributing factor is the poor treatment that many IDUs have experienced from law enforcement services and medical personnel. The negative view of IDUs among many in the medical community 27 necessitates that medical personnel consider the complex socioeconomic obstacles that placed the patient in the risk category to begin with. This mistrust represents an additional obstacle to the diagnosis and delivery of health care, including HCV antiviral therapy. Recent guidelines and commentaries have clearly stated that ongoing substance abuse should not preclude consideration for treatment 2829. This attitude has resonated within the community of health care professionals delivering HCV care, which seem more willing to consider treatment in this population, assuming that a reasonable degree of stability in substance use has been achieved by the patient.

A further concern for physicians dealing with HCV IDU patients is the patient's exposure to physical and sexual violence 30. Populations at risk for physical and sexual violence are at a heightened risk for exposure to HIV and viral hepatitis infections. Although intervening on behalf of patients by physicians is challenging, we should be aware that this population is at an increased risk for violence and that initial intake discussions should specifically target issues of physical and sexual violence.

Therapeutic outcome

Influence of injection drug use

For patients no longer using injection drugs, the success of therapy is determined by the same predictors (e.g. adherence, genotype) as those without a history of injection drug use. For those with active use, issues related to adherence, tolerance and effectiveness, psychological health, and risk of re-infection are important considerations.

In general, adherence to antimicrobial therapy is diminished in active drug users 313233. However, studies demonstrate that adherence varies widely among IDU patients and can, in some cases, approach that of populations without substance abuse 343536. Programs with special expertise in providing care for drug users can increase adherence rates to as high as 80% 373839404142.

There is little conclusive data to suggest that HCV antiviral therapy is tolerated less well or is less effective in those with concurrent injection use. In fact, in one study, sustained virological response rates comparable to other HCV-treated populations were achieved despite relapses to drug use in 80% of the patients receiving therapy 43. This group attributed their success to providing multidisciplinary care that included expertise in liver disease and substance abuse management. Other studies replicate these findings. A 29% sustained virological response rate was achieved in a population of 66 methadone recipients 44. This cohort had a high level of concurrent psychiatric illness (80%), concurrent alcohol use while on therapy (20%) and one-third relapsed into illicit drugs use. Therapy was effectively and safely delivered by provision of mental health care and appropriate resources to stabilize ongoing substance use.

Re-infection is often cited as justification to withhold HCV antiviral treatment from those with ongoing injection drug use. Although there is a risk and documented examples of have been cited 45, re-infection is a rare occurrence. HCV is generally acquired early in the career of an IDU as a result of inexperience and lack of knowledge regarding safe injecting techniques. Most patients presenting to clinic for therapy have a long history of injection drug use and are therefore less likely to commit the same errors in safe needle use as their junior counterparts. Of course, education and support for safe injection practices is an important component of care delivery to those treated for HCV infection. Support for safe injection facilities, needle exchange programs and provision of injection equipment have been demonstrated to reduce infection rates 46474849. It is reasonable to assume that this benefit would extend to those who successfully clear HCV with antiviral therapy.

Influence of alcohol on HCV treatment

Alcohol consumption impairs the efficacy of interferon-based HCV therapy 5051. There are several ways in which alcohol is thought to produce this negative influence on treatment outcomes. Most studies suggest that excess alcohol consumption increases HCV RNA levels 525354555657. In mice, alcohol consumption blunts HCV-specific T-helper and cytotoxic T lymphocytes response as well as cytokine expression 5859. Furthermore, decreased interferon-γ levels, resulting from alcohol-induced dendritic cell dysfunction 5960 likely influence HCV RNA levels. Both HCV RNA level and immune status predict sustained virologic response rates to interferon-based HCV treatment.

Although ongoing controlled alcohol (or other substance abuse) should not preclude HCV drug therapy 46, cessation of alcohol use should be emphasized as a highly beneficial therapeutic intervention. Physicians are in an optimal situation to encourage alcohol reduction strategies and brief discussions with patients may reduce alcohol intake 61. With successful alcohol reduction, liver inflammation and fibrosis will be reduced, HCV RNA levels will decline, and the probability of response to HCV drug therapy will be increased. This intervention requires sustained patient and physician commitment to alcohol cessation programs and patience.

Other substances of concern

Influence of smoking and marijuana use

High rates of cigarette smoking have been reported among HCV patients in Canada, Europe, and the Far East18626364. In our own cohort, the rate of cigarette smoking (63%) reported in HCV infection was much higher than the Canadian national average rate of 24% 1865. Smoking is also common among injection drug users 66.

Cigarette smoking has many known negative health consequences 67 and has been consistently associated with reduced health-related quality of life 186768. The negative physical effects of smoking have been found to be more severe in those with chronic medical conditions, including liver disease. In a cross-sectional study of 6095 individuals with HCV, cigarette smoking along with alcohol abuse were both independently associated with elevated ALT levels 69. Tobacco smoking has also been linked to hepatocellular carcinoma 2122 and increased Knodell fibrosis 63. Among Japanese patients with chronic liver disease (67% were HCV positive), hepatocellular carcinoma was higher for smokers and was independent of alcohol use (Relative Risk 15.4) 22. Smoking may also increase histological activity in chronic HCV patients irrespective of alcohol use 70. These findings justify further systematic assessment of the impact of smoking on those living with chronic liver disease.

Cigarette smoking has been associated with clinically relevant decrements in physical and mental health-related quality of life in those chronically infected with HCV 1871. Given that cigarette smoking is a modifiable health behavior, these findings may have important clinical implications. Smoking cessation interventions may help improve health-related quality of life for those with HCV-infection 7273. Further study of the effectiveness of psychological and/or pharmacological treatments for smoking cessation and relapse prevention, and the impact of these interventions on HCV patients' long-term health-related quality of life are justified.

The tar in marijuana contains similar carcinogens to those found in tobacco cigarettes 74. Furthermore, marijuana smoking has been associated with increased risk of head and neck cancer 74. To be fair, patient testimony suggests that marijuana many play a valuable role in attenuating the many side effects associated with interferon and ribavirin-based HCV treatment. In fact, treatment outcomes have been reported to be improved in those using marijuana compared to those not 44. Future research on the influence of marijuana smoking on liver disease progression, HCV health-related quality of life and HCV treatment efficacy should be pursued.

Influence of HIV co-infection on HCV progression and treatment

As a result of common risk factors for exposure, HCV and HIV are often found concurrently. The pace of HCV-induced hepatic fibrosis is accelerated in those with HIV co-infection 775. As a result, the burden of end stage liver disease and liver-related death is increased 7677. For these reasons, HCV treatment evaluation is essential in those with HIV-HCV co-infection. The likelihood of successfully clearing HCV infection with interferon and ribavirin-based therapy is diminished in those with HIV co-infection, even with well managed HIV disease 7879. Treatment side effects are not inconsequential but, in general, not substantially more plentiful or severe in co-infection 7879. Traditionally, there have been concerns pertaining to interactions between ribavirin and HIV antiretrovirals 8081. As didanosine, stavudine and zidovudine use diminish as safer alternates become available, concerns about nucleoside drug interactions with ribavirin have diminished. It is clear that pegylated interferon use in this immune compromised population does not result in a greater risk of infectious complications or HIV-defining opportunistic infections 7882.

Research priorities

Investigation and validation of treatment strategies which will improve adherence to viral hepatitis drug therapy are required to ensure that individuals who use injection drugs or other substances of abuse derive the maximal possible benefits from current viral hepatitis therapies. Given the wide spread use of medicinal marijuana in this population, quantification of the benefits and negative consequences of regular, long term use is mandatory. Rigorous evaluation of the safety, purported benefits and effect on quality of life are required for the many alternative and herbal remedies used by those living with HCV.

Many patients seek alternative sources of health care for a variety of reasons, including cultural relations, belief-systems, the concept of detoxifying their liver, and the potential therapeutic benefits of alternative therapies. Acupuncture, a traditional Asian intervention, often used for addiction and substance cravings, has been evaluated in a number of randomized trials. The evidence, has however, shown consistently that acupuncture is ineffective in addictive drug use 8384. A popular herbal medicine used by patients with liver disorders, including HCV, is Milk Thistle (Silybum marianum). Although the safety of Milk Thistle is now largely established 85, the therapeutic effectiveness is still uncertain. Some evidence suggests that it has therapeutic effectiveness in hepatitis B/C in reducing liver-related mortality. However, better quality studies indicate this result is uncertain 86. There are currently large trials enrolling HCV patients to determine Milk Thistle's impact on HCV specific outcomes.

It is plausible that the course and outcome of HCV many differ in those infected by injection drug use. Inoculum size and frequency of exposure may perturb the viral-host immune interaction. The poor nutrition status of injection drug uses may influence HCV pathogenesis and response to therapy. Well-designed analyses of this issue, which control for key confounders including alcohol use and nutritional status would provide clarity.

The need to implement interventions to reduce the infection rate of HCV among IDUs is critical. Although ongoing research is vital to ensure optimal application of techniques to limit the spread of HCV in this high risk group, this should not be used as an excuse to delay introduction of practices which are now well known to be effective) 46474849.

Conclusion

HCV infection in the IDU population is a major medical concern, one that is likely to remain for the foreseeable future. The difficulties of delivering current interferon-based HCV treatment to this population are well known. Co-morbid mental health concerns, concurrent substance use and abuse, poor socioeconomic status, exposure to violence and a treatment protocol that is often not compatible with the schedules of injection drug users combine to account for poor uptake and completion of HCV treatment. Moral and financial support from government for this disenfranchised population would perhaps provide the greatest impetus to allow for successful delivery of HCV treatment to this population. In a more favorable climate, practices demonstrated to reduce harmful behavior and effectively manage the above risk factors and co-morbidities in the IDU population could produce improvement in individual and population health. This, in turn would make HCV drug treatment more accessible to a larger proportion of those requiring therapy.

The prevalence of hepatitis in Canada Remis RS , Health Canada 2003 Hepatitis C virus: epidemiology and transmission Heintges T Wands JR Hepatology 1997 26 521 526 10.1002/hep.510260338 9303478 Epidemiology of hepatitis C virus infection in Canada, 2002: March 27-31; Vancouver, B.C.. Remis 2004 The natural history of hepatitis C virus infection: host, viral, and environmental factors Thomas DL Astemborski J Rai RM Anania FA Schaeffer M Galai N Nolt K Nelson KE Strathdee SA Johnson L Laeyendecker O Boitnott J Wilson LE Vlahov D Jama 2000 284 450 456 10.1001/jama.284.4.450 10904508 Alcohol and HIV risk taking among intravenous drug users Stein MD Charuvastra A Anderson B Sobota M Friedmanna PD Addict Behav 2002 27 727 736 10.1016/S0306-4603(01)00205-2 12201380 Adverse drinking consequences among alcohol abusing intravenous drug users Anderson BJ Gogineni A Charuvastra A Longabaugh R Stein MD Alcohol Clin Exp Res 2001 25 41 45 10.1111/j.1530-0277.2001.tb02125.x 11198713 Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group Benhamou Y Bochet M Di Martino V Charlotte F Azria F Coutellier A Vidaud M Bricaire F Opolon P Katlama C Poynard T Hepatology 1999 30 1054 1058 10.1002/hep.510300409 10498659 Estimating progression to cirrhosis in chronic hepatitis C virus infection Freeman AJ Dore GJ Law MG Thorpe M Von Overbeck J Lloyd AR Marinos G Kaldor JM Hepatology 2001 34 809 816 10.1053/jhep.2001.27831 11584380 Clinical outcomes after transfusion-associated hepatitis C Tong MJ el-Farra NS Reikes AR Co RL N Engl J Med 1995 332 1463 1466 10.1056/NEJM199506013322202 7739682 Different degrees of malnutrition and immunological alterations according to the aetiology of cirrhosis: a prospective and sequential study Caly WR Strauss E Carrilho FJ Laudanna AA Nutr J 2003 2 10 270012 14613508 10.1186/1475-2891-2-10 Alcohol and the liver: 1994 update Lieber CS Gastroenterology 1994 106 1085 1105 8143977 Malnutrition in cirrhosis Muller MJ J Hepatol 1995 23 Suppl 1 31 35 8551009 Nutritional assessment in intravenous drug users with HIV/AIDS Smit E Tang A J Acquir Immune Defic Syndr 2000 25 Suppl 1 S62 9 10.1097/00042560-200010001-00010 11126429 Drug abuse and psychiatric comorbidity Kokkevi A Stefanis C Compr Psychiatry 1995 36 329 337 10.1016/S0010-440X(95)90113-2 7497706 Depression, fatigue, and functional disability in patients with chronic hepatitis C Dwight MM Kowdley KV Russo JE Ciechanowski PS Larson AM Katon WJ J Psychosom Res 2000 49 311 317 10.1016/S0022-3999(00)00155-0 11164055 Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review Dieperink E Willenbring M Ho SB Am J Psychiatry 2000 157 867 876 10.1176/appi.ajp.157.6.867 10831463 Treating hepatitis C in methadone maintenance patients: an interim analysis Sylvestre DL Drug Alcohol Depend 2002 67 117 123 10.1016/S0376-8716(02)00010-8 12095661 Depression and cigarette smoking independently contribute to reduced quality of life among Canadians living with hepatitis C. Balfour L Cooper C Kowal J Tasca GA Silverman AL Kane M Garber G Can J Gastroenterol In press 2005 The CED-D scale: a self-report depression scale for research in the general population. Radloff LS Applied Psychological Measurements 1977 1 385 401 Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms Bonaccorso S Puzella A Marino V Pasquini M Biondi M Artini M Almerighi C Levrero M Egyed B Bosmans E Meltzer HY Maes M Psychiatry Res 2001 105 45 55 10.1016/S0165-1781(01)00315-8 11740974 Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma Kuper H Tzonou A Kaklamani E Hsieh CC Lagiou P Adami HO Trichopoulos D Stuver SO Int J Cancer 2000 85 498 502 10.1002/(SICI)1097-0215(20000215)85:4<498::AID-IJC9>3.0.CO;2-F 10699921 Chronic liver diseases for the risk of hepatocellular carcinoma: a case-control study in Japan. Etiologic association of alcohol consumption, cigarette smoking and the development of chronic liver diseases Mukaiya M Nishi M Miyake H Hirata K Hepatogastroenterology 1998 45 2328 2332 9951917 Effect of smoking, alcohol, and depression on the quality of life of head and neck cancer patients Duffy SA Terrell JE Valenstein M Ronis DL Copeland LA Connors M Gen Hosp Psychiatry 2002 24 140 147 10.1016/S0163-8343(02)00180-9 12062138 Depressive symptomatology and smoking among persons with diabetes Haire-Joshu D Heady S Thomas L Schechtman K Fisher EB Jr. Res Nurs Health 1994 17 273 282 8036275 A randomized, placebo controlled trial of citalopram for the prevention of depression and its consequences in HIV-Hepatitis C co-infected individuals initiating pegylated interferon/ribavirin therapy. Klein M Cooper C Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C Schaefer M Schwaiger M Garkisch AS Pich M Hinzpeter A Uebelhack R Heinz A van Boemmel F Berg T J Hepatol 2005 42 793 798 10.1016/j.jhep.2005.01.020 15885349 Medical care for injection-drug users with human immunodeficiency virus infection O'Connor PG Selwyn PA Schottenfeld RS N Engl J Med 1994 331 450 459 10.1056/NEJM199408183310707 8035842 National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002 Seeff LB Hoofnagle JH Hepatology 2002 36 S1 2 10.1002/hep.1840360702 12407571 Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? Edlin BR Seal KH Lorvick J Kral AH Ciccarone DH Moore LD Lo B N Engl J Med 2001 345 211 214 1510901 11463019 10.1056/NEJM200107193450311 Sexual violence among a cohort of injection drug users Braitstein P Li K Tyndall M Spittal P O'Shaughnessy MV Schilder A Johnston C Hogg RS Schechter MT Soc Sci Med 2003 57 561 569 10.1016/S0277-9536(02)00403-3 12791497 Non-adherence in tuberculosis treatment: predictors and consequences in New York City. Pablos-Mendez A Knirsch CA Barr RG Lerner BH Frieden TR Am J Med 1997 102 164 170 10.1016/S0002-9343(96)00402-0 9217566 The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. Haubrich RH Little SJ Currier JS Forthal DN Kemper CA Beall GN Johnson D Dube MP Hwang JY McCutchan JA Aids 1999 13 1099 1107 10.1097/00002030-199906180-00014 10397541 Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection Lucas GM Cheever LW Chaisson RE Moore RD J Acquir Immune Defic Syndr 2001 27 251 259 11464144 The magnitude of compliance and noncompliance. Sackett DL SNow JC Compliance in Health Care Baltimore, Johns Hopkins University Press Haynes RB, Taylor DW and Sackett DL 1979 11 22 Compliance with treatment regimens in chronic asymptomatic diseases Miller NH Am J Med 1997 102 43 49 10.1016/S0002-9343(97)00467-1 9217586 Inhaled corticosteroids for asthma therapy: patient compliance, devices, and inhalation technique Cochrane MG Bala MV Downs KE Mauskopf J Ben-Joseph RH Chest 2000 117 542 550 10.1378/chest.117.2.542 10669701 A cohort study of drug users' compliance with zidovudine treatment Broers B Morabia A Hirschel B Arch Intern Med 1994 154 1121 1127 10.1001/archinte.154.10.1121 8185425 Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type 1: a cross-sectional study in a municipal hospital clinic Samet JH Libman H Steger KA Dhawan RK Chen J Shevitz AH Dewees-Dunk R Levenson S Kufe D Craven DE Am J Med 1992 92 495 502 10.1016/0002-9343(92)90746-X 1580296 High compliance with a hepatitis B virus vaccination program among intravenous drug users Mezzelani P Venturini L Turrina G Lugoboni F Des Jarlais DC J Infect Dis 1991 163 923 1826302 Predictors of adherence to tuberculosis treatment in a supervised therapy programme for prisoners before and after release. Study Group of Adherence to Tuberculosis Treatment of Prisoners Marco A Cayla JA Serra M Pedro R Sanrama C Guerrero R Ribot N Eur Respir J 1998 12 967 971 10.1183/09031936.98.12040967 9817177 Incentives and accessibility: a pilot study to promote adherence to TB prophylaxis in a high-risk community Lorvick J Thompson S Edlin BR Kral AH Lifson AR Watters JK J Urban Health 1999 76 461 467 10.1007/BF02351503 10609595 Medical eligibility, comprehension of the consent process, and retention of injection drug users recruited for an HIV vaccine trial Harrison K Vlahov D Jones K Charron K Clements ML J Acquir Immune Defic Syndr Hum Retrovirol 1995 10 386 390 7552502 Treatment of hepatitis C infection in injection drug users Backmund M Meyer K Von Zielonka M Eichenlaub D Hepatology 2001 34 188 193 10.1053/jhep.2001.25882 11431750 Treatment of HCV in the methadone patient.: April 26-28; Chicago, Illinois. Sylvestre DL American Association for the Study of Liver Diseases 2002 103 107 Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up Dalgard O Bjoro K Hellum K Myrvang B Skaug K Gutigard B Bell H Eur Addict Res 2002 8 45 49 10.1159/000049487 11818693 Prevention and treatment of hepatitis C in injection drug users Edlin BR Hepatology 2002 36 S210 9 1629041 12407596 10.1002/hep.1840360727 Physician prescribing of sterile injection equipment to prevent HIV infection: time for action Burris S Lurie P Abrahamson D Rich JD Ann Intern Med 2000 133 218 226 10906838 The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis Marsch LA Addiction 1998 93 515 532 10.1046/j.1360-0443.1998.9345157.x 9684390 Centres for Disease Control. Fact Sheet: physician prescription of sterile syringes to injection drug users[on-line]. Available: http://www.cdc.gov/idu/facts/physician.htm) Academy of Educational Development Hepatitis C and alcohol: interactions, outcomes, and implications Bhattacharya R Shuhart MC J Clin Gastroenterol 2003 36 242 252 10.1097/00004836-200303000-00012 12590237 Alcohol abstinence does not offset the strong negative effect of lifetime alcohol consumption on the outcome of interferon therapy Tabone M Sidoli L Laudi C Pellegrino S Rocca G Della Monica P Fracchia M Galatola G Molinaro GC Arico S Pera A J Viral Hepat 2002 9 288 294 10.1046/j.1365-2893.2002.00360.x 12081606 Increase in hepatitis C virus load in hemophiliacs during treatment with highly active antiretroviral therapy Ragni MV Bontempo FA J Infect Dis 1999 180 2027 2029 10.1086/315143 10558963 Increased serum hepatitis C virus RNA levels among alcoholic patients with chronic hepatitis C Oshita M Hayashi N Kasahara A Hagiwara H Mita E Naito M Katayama K Fusamoto H Kamada T Hepatology 1994 20 1115 1120 10.1016/0270-9139(94)90745-5 7523270 Chronic hepatitis C: effect of alcohol on hepatitic activity and viral titre Cromie SL Jenkins PJ Bowden DS Dudley FJ J Hepatol 1996 25 821 826 10.1016/S0168-8278(96)80284-4 9007708 Effect of alcohol use on the impact of effective antiretroviral therapy for HIV co-infection on plasma HCV levels Cooper C Cameron DW Clin Infect Dis 2005 41 S105 109 10.1086/429506 16265607 Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic Lucas GM Gebo KA Chaisson RE Moore RD AIDS 2002 16 767 774 10.1097/00002030-200203290-00012 11964533 Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C Pessione F Degos F Marcellin P Duchatelle V Njapoum C Martinot-Peignoux M Degott C Valla D Erlinger S Rueff B Hepatology 1998 27 1717 1722 10.1002/hep.510270635 9620348 Inhibitory effects of chronic ethanol consumption on cellular immune responses to hepatitis C virus core protein are reversed by genetic immunizations augmented with cytokine-expressing plasmids Geissler M Gesien A Wands JR J Immunol 1997 159 5107 5113 9366440 Reduced alloreactive T-cell activation after alcohol intake is due to impaired monocyte accessory cell function and correlates with elevated IL-10, IL-13, and decreased IFNgamma levels Szabo G Mandrekar P Dolganiuc A Catalano D Kodys K Alcohol Clin Exp Res 2001 25 1766 1772 10.1111/j.1530-0277.2001.tb02188.x 11781510 Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection Bain C Fatmi A Zoulim F Zarski JP Trepo C Inchauspe G Gastroenterology 2001 120 512 524 10.1053/gast.2001.21212 11159892 Effectiveness of opportunistic brief interventions for problem drinking in a general hospital setting: systematic review Emmen MJ Schippers GM Bleijenberg G Wollersheim H Bmj 2004 328 318 338095 14729657 10.1136/bmj.37956.562130.EE Biopschosocial predictors of health-related quality of life in patients with chronic hepatitis C. Winfried H Zimmer C Schiedermaier P Grandt D Psychosom Med 2004 66 954 958 10.1097/01.psy.0000145824.82125.a8 15564364 Cigarette smoking and hepatic lesions in patients with chronic hepatitis C Pessione F Ramond MJ Njapoum C Duchatelle V Degott C Erlinger S Rueff B Valla DC Degos F Hepatology 2001 34 121 125 10.1053/jhep.2001.25385 11431742 Hepatitis C virus infection: impacts on behaviour and lifestyle Sladden TJ Hickey AR Dunn TM Beard JR Aust N Z J Public Health 1998 22 509 511 9659782 Canadian tobacco use monitoring survey (CTUMS): prevalence 2000-2002. Canada H 2000 Interest in smoking cessation among injection drug users Clarke JG Stein MD McGarry KA Gogineni A Am J Addict 2001 10 159 166 10.1080/105504901750227804 11444157 Influence of smoking on the health status of spinal patients: the National Spine Network database Vogt MT Hanscom B Lauerman WC Kang JD Spine 2002 27 313 319 10.1097/00007632-200202010-00022 11805698 Development of the Smoking Cessation Quality of Life questionnaire Olufade AO Shaw JW Foster SA Leischow SJ Hays RD Coons SJ Clin Ther 1999 21 2113 2130 10.1016/S0149-2918(00)87242-2 10645757 Smoking and alanine aminotransfererase levels in hepatitis C virus infection: implications for prevention of hepatitis C virus progression. Wang CS Wang ST Chang TT Yao WJ Chou P Arch Intern Med 2002 162 811 815 10.1001/archinte.162.7.811 11926856 Impact of smoking on histological liver lesions in chronic hepatitis C Hezode C Lonjon I Roudot-Thoraval F Mavier JP Pawlotsky JM Zafrani ES Dhumeaux D Gut 2003 52 126 129 10.1136/gut.52.1.126 12477773 Health-state utilities and quality of life in hepatitis C patients Chong CA Gulamhussein A Heathcote EJ Lilly L Sherman M Naglie G Krahn M Am J Gastroenterol 2003 98 630 638 10.1111/j.1572-0241.2003.07332.x 12650799 Individual behavioural counselling for smoking cessation Lancaster T Stead LF Cochrane Database Syst Rev 2005 CD001292 15846616 Smoking and smoking cessation Fisher EB Jr. Haire-Joshu D Morgan GD Rehberg H Rost K Am Rev Respir Dis 1990 142 702 720 2202249 Marijuana smoking and head and neck cancer Hashibe M Ford DE Zhang ZF J Clin Pharmacol 2002 42 103S 107S 12412843 Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection Lesens O Deschenes M Steben M Belanger G Tsoukas CM J Infect Dis 1999 179 1254 1258 10.1086/314720 10191232 Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection Qurishi N Kreuzberg C Luchters G Effenberger W Kupfer B Sauerbruch T Rockstroh JK Spengler U Lancet 2003 362 1708 1713 10.1016/S0140-6736(03)14844-1 14643119 Mortality in the Highly Active Antiretroviral Therapy Era: Changing Causes of Death and Disease in the HIV Outpatient Study Palella FJ Jr. Baker RK Moorman AC Chmiel JS Wood KC Brooks JT Holmberg SD J Acquir Immune Defic Syndr 2006 43 27 34 10.1097/01.qai.0000233310.90484.16 16878047 Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients Torriani FJ Rodriguez-Torres M Rockstroh JK Lissen E Gonzalez-Garcia J Lazzarin A Carosi G Sasadeusz J Katlama C Montaner J Sette H Jr. Passe S De Pamphilis J Duff F Schrenk UM Dieterich DT N Engl J Med 2004 351 438 450 10.1056/NEJMoa040842 15282351 Pegylated Interferon Alfa-2b vs Standard Interferon Alfa-2b, Plus Ribavirin, for Chronic Hepatitis C in HIV_Infected Patients Carrat F Bani-Sadr F Pol S al. Jama 2004 292 2839 2848 10.1001/jama.292.23.2839 15598915 Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection Lafeuillade A Hittinger G Chadapaud S Lancet 2001 357 280 281 10.1016/S0140-6736(00)03618-7 11214134 Mitochondrial toxic effects and ribavirin Salmon-Ceron D Chauvelot-Moachon L Abad S Silbermann B Sogni P Lancet 2001 357 1803 1804 10.1016/S0140-6736(00)04921-7 11407389 Rate of infectious complications during interferon-based therapy for hepatitis C is not related to neutropenia Cooper CL Al-Bedwawi S Lee C Garber G Clin Infect Dis 2006 42 1674 1678 10.1086/504386 16705570 A meta-analysis of studies into the effect of acupuncture on addiction Ter Riet G Kleijnen J Knipschild P Br J Gen Pract 1990 40 379 382 1371348 2148263 Efficacy of acupuncture for cocaine dependence: a systematic review & meta-analysis Mills EJ Wu P Gagnier J Ebbert JO Harm Reduct J 2005 2 4 1079914 15771785 10.1186/1477-7517-2-4 Milk thistle and indinavir: a randomized controlled pharmacokinetics study and meta-analysis Mills E Wilson K Clarke M Foster B Walker S Rachlis B DeGroot N Montori VM Gold W Phillips E Myers S Gallicano K Eur J Clin Pharmacol 2005 61 1 7 10.1007/s00228-004-0843-z 15666173 Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases Rambaldi A Jacobs BP Iaquinto G Gluud C Cochrane Database Syst Rev 2005 2